Comparison Overview

Ipca Laboratories Limited

VS

Grifols

Ipca Laboratories Limited

125 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, IN, 400067
Last Update: 2026-04-02
Between 750 and 799

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,559
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Grifols

Parc Empresarial Can Sant Joan, Sant Cugat del Vallès, 08174, ES
Last Update: 2026-03-30
Between 750 and 799

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,839
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Ipca Laboratories Limited
100%
Compliance Rate
0/4 Standards Verified
Grifols
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Ipca Laboratories Limited in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Grifols in 2026.

Incident History — Ipca Laboratories Limited (X = Date, Y = Severity)

Ipca Laboratories Limited cyber incidents detection timeline including parent company and subsidiaries

Incident History — Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
Incidents

No Incident

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
Incidents

No Incident

FAQ

Grifols company demonstrates a stronger AI Cybersecurity Score compared to Ipca Laboratories Limited company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Grifols company has disclosed a higher number of cyber incidents compared to Ipca Laboratories Limited company.

In the current year, Grifols company and Ipca Laboratories Limited company have not reported any cyber incidents.

Neither Grifols company nor Ipca Laboratories Limited company has reported experiencing a ransomware attack publicly.

Neither Grifols company nor Ipca Laboratories Limited company has reported experiencing a data breach publicly.

Neither Grifols company nor Ipca Laboratories Limited company has reported experiencing targeted cyberattacks publicly.

Neither Ipca Laboratories Limited company nor Grifols company has reported experiencing or disclosing vulnerabilities publicly.

Neither Ipca Laboratories Limited nor Grifols holds any compliance certifications.

Neither company holds any compliance certifications.

Grifols company has more subsidiaries worldwide compared to Ipca Laboratories Limited company.

Grifols company employs more people globally than Ipca Laboratories Limited company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Ipca Laboratories Limited nor Grifols holds SOC 2 Type 1 certification.

Neither Ipca Laboratories Limited nor Grifols holds SOC 2 Type 2 certification.

Neither Ipca Laboratories Limited nor Grifols holds ISO 27001 certification.

Neither Ipca Laboratories Limited nor Grifols holds PCI DSS certification.

Neither Ipca Laboratories Limited nor Grifols holds HIPAA certification.

Neither Ipca Laboratories Limited nor Grifols holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

nimiq/core-rs-albatross is a Rust implementation of the Nimiq Proof-of-Stake protocol based on the Albatross consensus algorithm. Prior to version 1.3.0, two peer-facing consensus request handlers assume that the history index is always available and call blockchain.history_store.history_index().unwrap() directly. That assumption is false by construction. HistoryStoreProxy::history_index() explicitly returns None for the valid HistoryStoreProxy::WithoutIndex state. when a full node is syncing or otherwise running without the history index, a remote peer can send RequestTransactionsProof or RequestTransactionReceiptsByAddress and trigger an Option::unwrap() panic on the request path. This issue has been patched in version 1.3.0.

Risk Information
cvss3
Base: 5.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

PraisonAI is a multi-agent teams system. Prior to version 1.5.95, FileTools.download_file() in praisonaiagents validates the destination path but performs no validation on the url parameter, passing it directly to httpx.stream() with follow_redirects=True. An attacker who controls the URL can reach any host accessible from the server including cloud metadata services and internal network services. This issue has been patched in version 1.5.95.

Risk Information
cvss3
Base: 8.6
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, OAuthManager.validate_token() returns True for any token not found in its internal store, which is empty by default. Any HTTP request to the MCP server with an arbitrary Bearer token is treated as authenticated, granting full access to all registered tools and agent capabilities. This issue has been patched in version 4.5.97.

Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, the PraisonAI Gateway server accepts WebSocket connections at /ws and serves agent topology at /info with no authentication. Any network client can connect, enumerate registered agents, and send arbitrary messages to agents and their tool sets. This issue has been patched in version 4.5.97.

Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.90, MCPToolIndex.search_tools() compiles a caller-supplied string directly as a Python regular expression with no validation, sanitization, or timeout. A crafted regex causes catastrophic backtracking in the re engine, blocking the Python thread for hundreds of seconds and causing a complete service outage. This issue has been patched in version 4.5.90.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H